论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
放射增敏药物在骨肉瘤治疗中的作用:机制与临床展望
Authors Zhang Y, Xie Y, Wang Y, Huang P, Lu Y
Received 16 December 2024
Accepted for publication 9 March 2025
Published 14 March 2025 Volume 2025:19 Pages 1927—1942
DOI https://doi.org/10.2147/DDDT.S512479
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Muzammal Hussain
Yilei Zhang,* Yuhuan Xie,* Yiwen Wang,* Panpan Huang, Yao Lu
School of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yao Lu; Panpan Huang, Email luy@gmu.edu.cn; huangpp@gmu.edu.cn
Abstract: Osteosarcoma is a highly malignant bone tumor that is resistant to radiotherapy and is associated with poor treatment outcomes and prognoses. Understanding the mechanisms of radioresistance and finding strategies to enhance the radiosensitivity is crucial for improving clinical efficacy. The aim of this review was to address the approaches for enhancing the efficacy of radiotherapy in osteosarcoma, thereby improving patient outcomes. Specifically, we have focused on the mechanisms of radiosensitization and the relationship between drugs that enhance radiosensitivity and cancer. These mechanisms involve a delay in DNA damage repair, promotion of apoptosis, inhibition of angiogenesis, and regulation of the tumor microenvironment. In addition, we have summarized the effects of these drugs on the proliferation, migration, invasion and apoptosis of osteosarcoma cell lines. Finally, we have discussed the therapeutic effects and adverse reactions of these drugs in other cancers, providing valuable guidance for clinical treatment strategies tailored to patients with osteosarcoma.
Keywords: osteosarcoma, radiotherapy, radiosensitization, cancer